Ancillary Events

What’s an Ancillary Event?
Ancillary events are independent educational symposia held in conjunction with ONS conferences. They are not official ONS events and are held outside of the hours of regular ONS activities to prevent scheduling conflicts.

Advances in the Treatment of Renal Cell Carcinoma: Optimizing Outcomes
Supported by an unrestricted educational grant from Bayer Pharmaceuticals and Onyx Pharmaceuticals

Angiogenesis Inhibitors in Solid Tumors
Supported by an unrestricted educational grant from Genentech BioOncology

Hereditary Cancer: Implications for Nurses
Supported by an unrestricted educational grant from Myriad Genetic Laboratories, Inc.

What’s on the Horizon for EGFR Inhibition? The Biology, The Patient, Your Clinical Practice
Supported by an unrestricted educational grant from Amgen, Inc.

Integrating Recent Advances in Colorectal Cancer Into Current Practice
Supported by an unrestricted educational grant from Sanofi-Aventis

NP Focused—Oncology Highlights 2005: Monoclonal Antibodies in Non-Hodgkin Lymphomas
Supported by an unrestricted educational grant from Genentech BioOncology and Biogen IDEC

The Evolution of Targeted Therapies for the Treatment of Breast Cancer
Supported by an unrestricted educational grant from Genentech BioOncology

Emerging Role of Targeted Therapies for the Treatment of Renal Cell Carcinoma
Supported by an unrestricted educational grant from Pfizer

NP Focused—Oncology Highlights 2005: Updated Clinical Research on Erythropoietic Agents for Chemotherapy-Induced Anemia
Supported by an unrestricted educational grant from Ortho Biotech

Three Is a Crowd: Clinical Use and Management of Combined Taxane and Targeted Therapy in Breast, NSCLC, and Prostate Cancer
Supported by an unrestricted educational grant from Sanofi-Aventis

NP Focused—Oncology Highlights 2005: Targeted Therapy for the Treatment of Breast Cancer
Supported by an unrestricted educational grant from Genentech BioOncology

Let's Talk About Our Patients… Best Practices for Assessment and Proactive Management of Chemotherapy-Induced Neutropenia
Supported by an unrestricted educational grant from Amgen, Inc.

Soaring New Heights With Anti-EGFR Therapy: From Initiating Treatment to Conquering Management Strategies
Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated

Nanotechnology and Metastatic Breast Cancer: Discover New Treatment Options
Supported by an unrestricted educational grant from Abraxis Oncology

Case-Based Discussions in Symptom Management: CINV and Oral Mucositis
Supported by an unrestricted educational grant from MGI Pharma

Optimizing Communication and Extended Adjuvant Therapy for Women With Breast Cancer
Supported by an unrestricted educational grant from Novartis Oncology

Current Topics in Myelodysplastic Syndromes
Supported by an unrestricted educational grant from MGI Pharma

A Clinical Forum on CINV: Achieving Improved Patient Outcomes
Supported by an unrestricted educational grant from Merck & Co., Inc.

Targeting Tumor Lysis Syndrome: New Therapeutic Options
Supported by an unrestricted educational grant from Sanofi-Aventis